Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease - Takeaways - MDSpire

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

  • By

  • Qiumei Zhu

  • Shitao Feng

  • Zhende Yan

  • Zijian Wang

  • Xinran Huang

  • Changning Sun

  • Bingqiang Zhang

  • Xinrui Li

  • Yuchao Gu

  • July 2, 2026

  • 0 min

Share

  • 1

    Escherichia coli Nissle 1917 was engineered to secrete the anti-TNF-α nanobody MT1, creating the single-strain platform EcN-MT1.

  • 2

    The α-hemolysin signal peptide achieved the highest secretion level of MT1 at 4.6 mg/L, outperforming genomic integrants.

  • 3

    EcN-MT1 demonstrated significant therapeutic efficacy in a DSS-induced murine colitis model, improving weight loss and disease activity index.

  • 4

    Histopathological analysis showed that EcN-MT1 reduced mucosal ulceration and immune cell infiltration while downregulating pro-inflammatory cytokines.

  • 5

    EcN-MT1 treatment restored gut microbial diversity and enriched beneficial taxa associated with anti-inflammatory effects.

Original Source(s)

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

  • by Qiumei Zhu, Shitao Feng, Zhende Yan, Zijian Wang, Xinran Huang, Changning Sun, Bingqiang Zhang, Xinrui Li, Yuchao Gu

  • July 2, 2026

Related Content

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in Behçet’s disease and inflammatory bowel disease

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo